Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis

Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis: A Randomized, Double-blind, Placebo-controlled Study

This trial is planned to investigate the efficacy and safety of Stapokibart (an IL-4 receptor antagonist) in patients with PCA.

Study Overview

• Status: Not yet recruiting
• Conditions: Primary Cutaneous Amyloidosis
• Intervention / Treatment: Biological: Stapokibart; Other: Placebo drug

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Males or females aged 18 to 75 years, with a diagnosis of PCA confirmed by skin biopsy, and an IGA score of ≥3, a AASI score of ≥5, and a BSA involvement of ≥5%.
2. Subjects who have received at least 4 weeks of mid-to-high potency or at least 2 weeks of very high potency topical corticosteroids (TCS) or an adequate course of systemic corticosteroids within the 6 months prior to screening, but with an inadequate response; or subjects who are unable to receive the above treatments due to adverse reactions or potential risks.
3. Prior to the first dose, subjects must have used a moisturizer continuously for at least 1 week, once daily, and must continue to use it throughout the study period.
4. Able to understand and complete study-related questionnaires.
5. Able to read, understand, and are willing to sign the informed consent form.
6. Willing and able to comply with study visits and related procedures.
7. Women of childbearing potential must agree to use contraception (such as intrauterine devices, oral contraceptives, or condoms) during the study and for 6 months after the study ends; must have a negative serum pregnancy test within 7 days before the first dose and must not be breastfeeding; male subjects must agree to use contraception during the study and for 6 months after the study ends.

Exclusion Criteria:

1. Use of any of the following treatments within 4 weeks prior to randomization: a. Immunosuppressants or immunomodulators, such as systemic corticosteroids, cyclosporine, mycophenolate mofetil, interferon gamma (IFN-γ), azathioprine, methotrexate, and Janus kinase (JAK) inhibitors; b. UV phototherapy; c. Systemic traditional Chinese medicine (TCM) treatment.
2. Use of topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), TCM, or phosphodiesterase 4 (PDE-4) inhibitors within 2 weeks prior to randomization.
3. Receipt of anti-IL-4R monoclonal antibodies, anti-IgE monoclonal antibodies, or other biologics within 12 weeks or 5 half-lives (whichever is longer) prior to randomization.
4. Receipt of live attenuated vaccines within 12 weeks prior to randomization or planned vaccination during the study period.
5. Use of antihistamines within 1 week prior to randomization (subjects who have been on a stable dose of antihistamines for at least 7 days prior to randomization and plan to continue during the study period may be included).
6. Receipt of allergen-specific immunotherapy (desensitization therapy) within 6 months prior to randomization.
7. Presence of any skin comorbidities that may interfere with study assessments, including but not limited to scabies, cutaneous T-cell lymphoma, psoriasis, etc.
8. Previous receipt of at least 12 consecutive doses of anti-IL-4Rα or IL-13 monoclonal antibodies with inadequate clinical response (defined as failure to achieve AASI 50 during treatment).
9. Presence of any other significant medical history that the investigator deems would pose a risk to the subject's safety or be poorly controlled if the subject participates in the study, in addition to PCA.
10. History of known or suspected immunosuppression (immunodeficiency), including a history of invasive opportunistic infections (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis), even if the infection has resolved; or unusual frequency, recurrence, or chronicity of infections (at the investigator's discretion).
11. Subjects with any type of active malignancy or a history of malignancy (except for cervical cancer that has been cured for more than 5 years prior to the screening period, or non-metastatic squamous cell carcinoma of the skin, basal cell carcinoma, and papillary thyroid cancer).
12. Presence of active Mycobacterium tuberculosis infection.
13. Subjects with severe liver or kidney function impairment during the screening period, such as aspartate aminotransferase or alanine aminotransferase >2 times the upper limit of normal (ULN), total bilirubin >1.5 times ULN, serum creatinine >1.2 times ULN, etc.
14. Presence of active hepatitis during the screening period, or positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) and HBV-DNA, or positive for hepatitis C virus (HCV) antibody and HCV-RNA.
15. Positive for HIV antibody during the screening period, or history of HIV infection.
16. Positive for Treponema pallidum antibody during the screening period (subjects who have undergone standard treatment and have a negative non-treponemal antigen serological test may participate in the study).
17. Participation in another clinical trial of a drug or medical device within 12 weeks prior to randomization.
18. Presence of chronic active or acute infection requiring systemic treatment with antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to randomization. After resolution of the infection, the subject may be re-screened once.
19. Subjects who plan to undergo major surgical procedures during the study period.
20. Pregnant or breastfeeding women.
21. Subjects with a history of alcoholism, drug abuse, or known drug dependence.
22. History of atopic keratoconjunctivitis involving the cornea.
23. Any medical or psychiatric conditions that the investigator deems would pose a risk to the subject, interfere with participation in the study, or confound the interpretation of study results.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Other: Placebo drug; Placebo drugs without Stapokibart
Experimental: Stapokibart	Biological: Stapokibart; A humanized monoclonal antibody that targets the interleukin (IL)-4 receptor subunit alpha

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The percentage of subjects achieving AASI-75 at Week 16 of treatment	AASI: Amyloidosis Area and Severity Index. The minimum and maximum values: 0-72. Higher scores mean more serious situations. AASI-75: A 75% or greater improvement from baseline in the AASI. The minimum and maximum values: 0%-100%. Higher scores mean a better outcome.	At the end of treatment at 16 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The percentage of subjects with a weekly average reduction of≥4 points in PP-NRS score at Week 16 of treatment compared to baseline	PP-NRS: Peak Pruritus Numerical Rating Scale. The minimum and maximum values: 0-10. Higher scores mean more serious situations.	At the end of treatment at 16 weeks
The percentage of subjects with an IGA score of 0 or 1 and a reduction of≥2 points compared to baseline.	IGA: Investigator Global Assessment. The minimum and maximum values: 0-4. Higher scores mean more serious situations.	At the end of treatment at 16 weeks
The percentage of subjects achieving AASI-50 compared to baseline.	AASI: Amyloidosis Area and Severity Index. The minimum and maximum values: 0-72. Higher scores mean more serious situations. AASI-50: A 50% or greater improvement from baseline in the AASI. The minimum and maximum values: 0%-100%. Higher scores mean a better outcome.	At the end of treatment at 16 weeks
The percentage of subjects with a weekly average reduction of≥3 points in PP-NRS score compared to baseline	PP-NRS: Peak Pruritus Numerical Rating Scale. The minimum and maximum values: 0-10. Higher scores mean more serious situations.	At the end of treatment at 16 weeks
Change rates in BSA involvement compared to baseline.	BSA: Body Surface Area. The minimum and maximum values: 0-100%. Higher scores mean more serious situations.	At the end of treatment at 16 weeks
Changes in DLQI scores compared to baseline.	DLQI: Dermatology Life Quality Index. The minimum and maximum values: 0-30. Higher scores mean more serious situations.	At the end of treatment at 16 weeks
Changes in absolute eosinophil counts in complete blood counts compared to baseline.		At the end of treatment at 16 weeks
Changes in IgE levels in complete blood counts compared to baseline.		At the end of treatment at 16 weeks
Changes in histopathology of skin lesions compared to baseline in some subjects		At the end of follow-up at 28 weeks

Other Outcome Measures

Outcome Measure	Time Frame
Safety Endpoints:Including the occurrence of AEs(Adverse Events),and abnormalities in laboratory tests,physical examinations,and vital signs.	At the end of treatment at 16 weeks

Collaborators and Investigators

• Sponsor: First Affiliated Hospital of Chongqing Medical University

Study record dates

Study Major Dates

• Study Start (Estimated): September 15, 2025
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: August 13, 2025
• First Submitted That Met QC Criteria: August 23, 2025
• First Posted (Estimated): August 27, 2025

Study Record Updates

• Last Update Posted (Estimated): August 27, 2025
• Last Update Submitted That Met QC Criteria: August 23, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Keywords: primary cutaneous amyloidosis; Stapokibart
• Additional Relevant MeSH Terms: Amyloidosis, Primary Cutaneous
• Other Study ID Numbers: CQMU-2025-215

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No